Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.

BACKGROUND The impact of varying degrees of extrathyroid extension (ETE), especially microscopic ETE (METE), on survival in thyroid carcinomas (TC) has not been well established. Our objective was to analyze ETE at the molecular and histologic levels and assess the effect of its extent on outcome. METHODS All cases of TC with ETE but without nodal metastases at presentation (NMP) were identified over a 20-year period and grouped into gross and METE. Twelve papillary thyroid carcinomas (PTCs) without ETE and NMP were also analyzed. Cases with paraffin tissues were subjected to mass spectrometry genotyping encompassing the most significant oncogenes in TC: 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, and AKT1, and other related genes were surveyed. RESULTS Eighty-one (10%) of 829 patients in the database had ETE and no NMP. There was a much higher frequency of poorly differentiated and anaplastic carcinomas (12/29, 41%) in patients with gross ETE than in those with METE (3/52, 6%) (p < 0.01). There was a higher disease-specific survival (DSS) in patients with METE than in those with gross ETE (p < 0.0001). Except for an anaplastic case, no recurrences were detected in 45 patients with METE, including 23 PTC patients followed up for a median of 10 years without radioactive iodine therapy. Within patients with gross invasion into trachea/esophagus, tumors with high mitotic activity and/or tumor necrosis correlated with worse DSS (p < 0.05). Fifty-six cases with ETE were genotyped as follows: BRAFV600E, 39 (70%); BRAFV600E-AKT1, 1 (1.8%); NRAS, 1 (1.8%); KRAS, 1 (1.8%); RET/PTC, 3 (5%); wild type, 11 (19.6%). Within PTCs, BRAF positivity rate increased the risk of ETE (p = 0.01). If PTC follicular variants are excluded, BRAF positivity does not correlate with ETE status within classical/tall cell PTC. CONCLUSION (i) PTCs with METE without NMP have an extremely low recurrence rate in contrast to tumors with gross ETE. (ii) High mitotic activity and/or tumor necrosis confers worse DSS even in patients stratified for gross ETE in trachea/esophagus. (iii) BRAF positivity correlates with the presence of ETE in PTC, but this relationship is lost within classical/tall cell PTC if follicular variants are excluded from the analysis.

[1]  A. Pinchera,et al.  Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. , 2006, Endocrine-related cancer.

[2]  A. Miyauchi,et al.  Prognostic Significance of Extrathyroid Extension of Papillary Thyroid Carcinoma: Massive but Not Minimal Extension Affects the Relapse-free Survival , 2006, World Journal of Surgery.

[3]  H. Hundeshagen,et al.  Risk Factors in Follicular Thyroid Carcinomas: A Retrospective Follow-up Study Covering a 14-Year Period with Emphasis on Morphological Findings , 1986, The American journal of surgical pathology.

[4]  L. Liotta,et al.  Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. , 1992, Human pathology.

[5]  Yuri E Nikiforov,et al.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  J. Shah,et al.  Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis , 2006, Cancer.

[7]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[8]  E. Kebebew,et al.  Anaplastic thyroid carcinoma , 2005, Cancer.

[9]  R. von Wasielewski,et al.  Rearrangement analysis in archival thyroid tissues: punching microdissection and artificial RET/PTC 1-12 transcripts. , 2007, The Journal of surgical research.

[10]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[11]  R. Komorowski,et al.  Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. , 1988, Human pathology.

[12]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  R. Spiro,et al.  Hürthle cell carcinoma: a critical histopathologic appraisal. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Larson,et al.  Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma , 2008, Cancer.

[15]  W. Lehman.  Tumors of the thyroid gland. , 1950, Northwest medicine.

[16]  T. Giordano,et al.  Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas , 2006, The American journal of surgical pathology.

[17]  C. Tomlinson,et al.  Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. , 2006, Cancer research.

[18]  A. Pupi,et al.  Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy , 1985, Cancer.